ENCOURAGING DATA SHOWING THE EFFECTIVENESS OF RESPIRATORY ILLNESS VACCINES

NIRSEVIMAB SHOWN TO BE 90% EFFECTIVE PREVENTION MEASURE

Early CDC surveillance data has shown that nirsevimab is 90% effective at preventing respiratory syncytial virus (RSV)-associated hospitalization in infants. RSV is the leading cause of hospitalization among U.S. infants. In August 2023, the CDC recommended nirsevimab, a long-acting monoclonal antibody, to protect infants less than 8 months old against RSV-associated lower respiratory tract infection in their first RSV season. To reduce the risk of RSV-associated hospitalization, infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

VACCINE EFFECTIVENESS OF UPDATED 2023-2024 COVID-19 VACCINES

A new CDC report finds that the updated (2023-2024) COVID-19 vaccines cut the risk in half for visiting the emergency department, urgent care, or being hospitalized with COVID-19 for most people. Everyone 6 months and older should get an updated COVID-19 vaccine, especially people 65 years or older and people with medical conditions that make them more likely to get very sick with COVID-19, such as weakened immune systems. Learn more about how to stay up to date with COVID-19 vaccines: Stay Up to Date with COVID-19 Vaccines